The Impact of the Tumor Microenvironment on the Effect of IL-1β Blockade in NSCLC: Biomarker Analyses from CANOPY-1 and CANOPY-N Trials.

Nevertheless, the three correlative analyses concerning CD8 + T-cell subgroups performed in CANOPY-1 samples (total CD8 count in tumor samples, T-cell phenotype, and inflamed T-cell gene signature) showed a trend for canakinumab benefit in patients with features indicative of reduced CD8 + T-cell infiltration, supporting the hypothesis that patients whose tumors have a low CD8 + T-cell infiltration may benefit from the addition of IL-1β inhibition to ICIs.

also in 53,322 other papers